PE20161071A1 - Hexahidrofuropirroles como inhibidores de pde1 - Google Patents
Hexahidrofuropirroles como inhibidores de pde1Info
- Publication number
- PE20161071A1 PE20161071A1 PE2016001246A PE2016001246A PE20161071A1 PE 20161071 A1 PE20161071 A1 PE 20161071A1 PE 2016001246 A PE2016001246 A PE 2016001246A PE 2016001246 A PE2016001246 A PE 2016001246A PE 20161071 A1 PE20161071 A1 PE 20161071A1
- Authority
- PE
- Peru
- Prior art keywords
- hexahydrofuropyrrols
- pde1 inhibitors
- compounds
- inhibitors
- pde1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a compuestos de formula I donde R1 es H, F, entre otros; R2 a R11 son H, alquilo C1-C3, entre otros. Es compuesto preferido (3aS, 6aS)-4-(7,8-dimetoxiquinazolin-4-il)hexahidro-2H-furo[3,2-b]pirrol. Dichos compuestos son inhibidores de enzimas PDE1, siendo utiles en el tratamiento de trastornos neurodegenerativos y psiquiatricos tales como Alzheimer, esquizofrenia, entre otros
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400069 | 2014-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161071A1 true PE20161071A1 (es) | 2016-10-30 |
Family
ID=58698416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001246A PE20161071A1 (es) | 2014-02-07 | 2015-02-06 | Hexahidrofuropirroles como inhibidores de pde1 |
Country Status (26)
Country | Link |
---|---|
US (1) | US9718832B2 (es) |
EP (1) | EP3102584B1 (es) |
JP (1) | JP6532880B2 (es) |
KR (1) | KR20160115931A (es) |
CN (1) | CN106414459B (es) |
AP (1) | AP2016009344A0 (es) |
AR (1) | AR099300A1 (es) |
AU (1) | AU2015214214A1 (es) |
CA (1) | CA2935470A1 (es) |
CL (1) | CL2016001959A1 (es) |
CR (1) | CR20160322A (es) |
DO (1) | DOP2016000179A (es) |
EA (1) | EA201691335A1 (es) |
EC (1) | ECSP16071574A (es) |
ES (1) | ES2711085T3 (es) |
GE (1) | GEP201706795B (es) |
HK (1) | HK1232214A1 (es) |
IL (1) | IL246718A0 (es) |
MA (1) | MA39230B1 (es) |
MX (1) | MX2016010168A (es) |
PE (1) | PE20161071A1 (es) |
PH (1) | PH12016501495A1 (es) |
RU (1) | RU2016130684A (es) |
SG (1) | SG11201606445YA (es) |
TW (1) | TW201611834A (es) |
WO (1) | WO2015118097A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6554116B2 (ja) | 2014-04-04 | 2019-07-31 | ハー・ルンドベック・アクチエゼルスカベット | Pde1阻害剤としてのハロゲン化キナゾリン−thf−アミン |
CN110337437B (zh) | 2016-12-28 | 2023-02-03 | 达特神经科学有限公司 | 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物 |
CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
JP2009542732A (ja) * | 2006-07-10 | 2009-12-03 | ハー・ルンドベック・アクチエゼルスカベット | 6,7−ジアルコキシキナゾリン、6,7−ジアルコキシフタラジンおよび6,7−ジアルコキシイソキノリンの(3−アリール−ピペラジン−1−イル)、(2−アリール−モルホリン−4−イル)および(2−アリール−チオモルホリン−4−イル)誘導体 |
US8354545B2 (en) * | 2007-12-14 | 2013-01-15 | Merck, Sharp & Dohme, Corp. | 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
-
2015
- 2015-02-02 TW TW104103370A patent/TW201611834A/zh unknown
- 2015-02-05 AR ARP150100339A patent/AR099300A1/es unknown
- 2015-02-06 US US15/116,743 patent/US9718832B2/en active Active
- 2015-02-06 JP JP2016550614A patent/JP6532880B2/ja active Active
- 2015-02-06 MX MX2016010168A patent/MX2016010168A/es unknown
- 2015-02-06 WO PCT/EP2015/052492 patent/WO2015118097A1/en active Application Filing
- 2015-02-06 KR KR1020167021342A patent/KR20160115931A/ko not_active Application Discontinuation
- 2015-02-06 RU RU2016130684A patent/RU2016130684A/ru not_active Application Discontinuation
- 2015-02-06 EA EA201691335A patent/EA201691335A1/ru unknown
- 2015-02-06 PE PE2016001246A patent/PE20161071A1/es not_active Application Discontinuation
- 2015-02-06 SG SG11201606445YA patent/SG11201606445YA/en unknown
- 2015-02-06 MA MA39230A patent/MA39230B1/fr unknown
- 2015-02-06 CA CA2935470A patent/CA2935470A1/en not_active Abandoned
- 2015-02-06 ES ES15705781T patent/ES2711085T3/es active Active
- 2015-02-06 AP AP2016009344A patent/AP2016009344A0/en unknown
- 2015-02-06 CN CN201580005675.8A patent/CN106414459B/zh active Active
- 2015-02-06 EP EP15705781.1A patent/EP3102584B1/en active Active
- 2015-02-06 GE GEAP201514236A patent/GEP201706795B/en unknown
- 2015-02-06 CR CR20160322A patent/CR20160322A/es unknown
- 2015-02-06 AU AU2015214214A patent/AU2015214214A1/en not_active Abandoned
-
2016
- 2016-07-11 IL IL246718A patent/IL246718A0/en unknown
- 2016-07-19 DO DO2016000179A patent/DOP2016000179A/es unknown
- 2016-07-28 PH PH12016501495A patent/PH12016501495A1/en unknown
- 2016-08-03 CL CL2016001959A patent/CL2016001959A1/es unknown
- 2016-09-05 EC ECIEPI201671574A patent/ECSP16071574A/es unknown
-
2017
- 2017-06-09 HK HK17105707.4A patent/HK1232214A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201606445YA (en) | 2016-09-29 |
WO2015118097A1 (en) | 2015-08-13 |
EP3102584A1 (en) | 2016-12-14 |
US9718832B2 (en) | 2017-08-01 |
MA39230B1 (fr) | 2018-04-30 |
US20160347759A1 (en) | 2016-12-01 |
JP6532880B2 (ja) | 2019-06-19 |
TW201611834A (en) | 2016-04-01 |
RU2016130684A (ru) | 2018-03-15 |
CL2016001959A1 (es) | 2017-02-24 |
AR099300A1 (es) | 2016-07-13 |
CN106414459B (zh) | 2018-08-03 |
EP3102584B1 (en) | 2019-01-16 |
DOP2016000179A (es) | 2016-09-30 |
AP2016009344A0 (en) | 2016-07-31 |
JP2017505328A (ja) | 2017-02-16 |
AU2015214214A1 (en) | 2016-07-14 |
KR20160115931A (ko) | 2016-10-06 |
GEP201706795B (en) | 2017-12-11 |
MX2016010168A (es) | 2016-10-07 |
CA2935470A1 (en) | 2015-08-13 |
PH12016501495A1 (en) | 2017-02-06 |
HK1232214A1 (zh) | 2018-01-05 |
IL246718A0 (en) | 2016-08-31 |
CN106414459A (zh) | 2017-02-15 |
EA201691335A1 (ru) | 2016-12-30 |
MA39230A1 (fr) | 2017-07-31 |
ECSP16071574A (es) | 2017-02-24 |
CR20160322A (es) | 2016-09-16 |
ES2711085T3 (es) | 2019-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
MX2022002579A (es) | Compuestos de aminotiazol como inhibidores de c- kit. | |
EA201991197A1 (ru) | БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit | |
EA201792535A1 (ru) | Гетероциклические амиды в качестве ингибиторов киназ | |
PH12015501934A1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
MX2017008529A (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
PE20150684A1 (es) | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) | |
EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
PH12016500643A1 (en) | New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl | |
EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
PE20160875A1 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
PE20151748A1 (es) | Inhibidores de bace1 | |
MA50375A (fr) | Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 | |
UY36226A (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
CR20170008A (es) | Compuestos de [1,2,4] triazol e imidazol sustituidos | |
SV2017005381A (es) | Compuestos de imidazopiridazina | |
MY182342A (en) | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b | |
CL2017001100A1 (es) | Nuevas triazolo[4,5-d]pirimidinas | |
EA201692544A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
EA201692496A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
PE20150707A1 (es) | Inhibidores de la beta-secretasa | |
UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |